Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
OccuRx is a biopharmaceutical company that focuses on the development of innovative therapeutic strategies.
Mirugen is a preclinical biotechnology company identifying the optimal set of cellular instructions to ask one cell type to become another.
Amaroq Therapeutics is a biotech firm developing cancer therapies targeting long non-coding RNAs.
George Medicines is a drug manufacturing company that improves the management of non-communicable diseases.
Denteric is developing a vaccine based on research conducted at the University of Melbourne.
CatalYm is a biotechnology company developing innovative immunotherapies for cancer patients.
TamoRx is a Biotech company that is focused on research and development of biological mechanism within cells for cancer treatment.
Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function.
Currus Biologics is a biotechnology company that develop CAR-T cell therapies for the treatment of solid tumour cancers.
Cincera Therapeutics is a privately held biotechnology company.
OncoRes Medical develops an imaging technology to provide intraoperative information available to surgeons.
Ena Respiratory researches and develops solutions to transform the treatment and prevention of respiratory infections.
NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function.
Vaxxas develops needle-free HD-MAP patches that use microprojections to deliver medicine directly to immune cells beneath the skin.
Allay Therapeutics offers analgesic products for post-surgical pain management and recuperation.
PolyActiva develops products that enable drug release from medical devices.
Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer.
Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers.
Pathios Therapeutics is a biotech company focused on the development of therapies for autoimmune diseases and cancer.
Aravax is an early stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy.
Okogen is a developer of ophthalmic anti-infective drugs.
Perx is a digital care management program that motivates high-risk members to stick to their care plans.
Respirion Pharmaceuticals is an early-stage biotechnology company focused on developing new treatments for respiratory diseases.
Lumonus is a healthcare company that offers Radiation Oncology, Radiation Therapy, and Cancer treatment technology-enabled services.
Brandon Capital has invested in 45 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Brandon Capital's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Pharmaceutical. The firm invests across 13 different industry categories.
Among tracked funding rounds, CatalYm received $150.0M in a Series D round. Brandon Capital's total known invested capital is $1.1B.
Brandon Capital's average investment size is $28.3M across its portfolio of 45 companies.
Recent Brandon Capital portfolio additions include OccuRx, Mirugen, Amaroq Therapeutics, George Medicines, Denteric. These companies were founded in 2020 or later.